ESMO Events 2024
Meetings(opens in new tab/window) | ESMO(opens in new tab/window)
Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.
ESMO European Lung Cancer Congress 2024(opens in new tab/window)
The European Lung Cancer Congress (ELCC 2024) is a collaborative effort of important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide. Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer(opens in new tab/window) H.T. Tran †, S. Heeke †, S. Sujit, N. Vokes, J. Zhang, M. Aminu, V.K. Lam, A. Vaporciyan, S.G. Swisher, M.C.B. Godoy, T. Cascone, B. Sepesi, D.L. Gibbons, J. Wu ‡, J.V. Heymach ‡
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial(opens in new tab/window) E. Felip, N. Altorki, C. Zhou, E. Vallières, A. Martínez-Martí, A. Rittmeyer, A. Chella, M. Reck, O. Goloborodko, M. Huang, R. Belleli, V. McNally, M.K. Srivastava, E. Bennett, B.J. Gitlitz, H.A. Wakelee
ESMO Open
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial(opens in new tab/window) S. Michels, B. Massutí, I. Vasyliv, J. Stratmann, J. Frank, A. Adams, E. Felip, C. Grohé, D. Rodriguez-Abreu, H. Bischoff, E. Carcereny i Costa, J. Corral †, E. Pereira, J. Fassunke, R.N. Fischer, A. Insa, S. Koleczko, L. Nogova, M. Reck, T. Reutter, R. Riedel, D. Schaufler, M. Scheffler, M. Weisthoff, M. Provencio, S. Merkelbach-Bruse, M. Hellmich, M. Sebastian, R. Büttner, T. Persigehl, R. Rosell, J. Wolf
Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study(opens in new tab/window) D.-W. Kang †, S.-K. Park †, Y.L. Yu, Y. Lee, D.H. Lee, S. Kang
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy(opens in new tab/window) A. Abed, A.B. Beasley, A.L. Reid, N. Law, L. Calapre, M. Millward, J. Lo, E.S. Gray
Immuno-Oncology and Technology
J. Dallmann, J. Freitag, C. Jung, K. Khinvasara, L. Merz, D. Peters, M. Schork, J.D. Beck
ESMO Real World Data and Digital Oncology
ESMO Guidance for Reporting Oncology real-World evidence (GROW)(opens in new tab/window) L. Castelo-Branco, A. Pellat †, D. Martins-Branco †, A. Valachis †, J.W.G. Derksen †, K.P.M. Suijkerbuijk, U. Dafni, T. Dellaporta, A. Vogel, A. Prelaj, R.H.H. Groenwold, H. Martins, R. Stahel, J. Bliss, J. Kather, N. Ribelles, F. Perrone, P.S. Hall, R. Dienstmann, C.M. Booth, G. Pentheroudakis ‡, S. Delaloge ‡, M. Koopman ‡
ESMO affiliated journals
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives(opens in new tab/window) Miriam Dorta-Suárez, Maria de Miguel, Oscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez-Abreu
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer(opens in new tab/window) Byoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, Gary L. Buchschacher, Koichi Goto, Tobias R. Overbeck, Herbert H.F. Loong, Cheng E. Chee, Pilar Garrido, Xiaorong Dong, Yun Fan, Shun Lu, Sven Schwemmers, Walter Bordogna, Harald Zeuner, Stuart Osborne, Thomas John
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives(opens in new tab/window) Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
ESMO's Journal Portfolio
While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.